• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by BioAtla Inc.

    4/24/25 4:09:21 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCAB alert in real time by email
    DEFA14A 1 bcab_defa_14a_2025_-_not.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the Securities

    Exchange Act of 1934 (Amendment No. )

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material Pursuant to §240.14a-12

    BioAtla, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒ No fee required

    ☐ Fee paid previously with preliminary materials

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     


     

    img23053642_0.jpg

     

     


     

     

    img23053642_1.jpg

     


    Get the next $BCAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCAB

    DatePrice TargetRatingAnalyst
    11/13/2024Buy → Neutral
    H.C. Wainwright
    9/15/2022$17.00Mkt Outperform
    JMP Securities
    5/5/2022$35.00 → $5.00Outperform → Neutral
    Credit Suisse
    3/21/2022$25.00Buy
    H.C. Wainwright
    10/15/2021$68.00Buy
    BTIG Research
    6/28/2021$75.00Buy
    ROTH Capital
    More analyst ratings

    $BCAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Vasquez Christian was granted 85,000 shares, increasing direct ownership by 44% to 276,696 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      3/13/25 4:12:55 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Short Jay M Phd was granted 431,000 shares, increasing direct ownership by 24% to 2,256,372 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      3/13/25 4:12:28 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Waldron Richard A was granted 100,000 shares, increasing direct ownership by 43% to 333,263 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      3/13/25 4:12:02 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Leadership Updates

    Live Leadership Updates

    See more
    • BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS

      SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Edward L. (Eddie) Williams has been appointed to the BioAtla Board of Directors and has agreed to serve on the Audit Committee of the Board.  Mr. Williams has extensive executive experience in the biopharmaceutical industry and as a member of the board of directors of a biotechnology company in late-stage clinical development. Jay M. Short, Ph.D., Chairman of the Board and Chief Executive Officer, stated, "Eddie's career of demonstrated success and knowledge in growing biopharmaceuti

      12/21/21 9:00:00 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by BioAtla Inc.

      SCHEDULE 13G/A - BioAtla, Inc. (0001826892) (Subject)

      5/20/25 2:26:28 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - BioAtla, Inc. (0001826892) (Filer)

      5/16/25 5:05:56 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by BioAtla Inc.

      424B3 - BioAtla, Inc. (0001826892) (Filer)

      5/16/25 4:22:32 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mcbrinn Sylvia bought $9,400 worth of shares (4,000 units at $2.35), increasing direct ownership by 26% to 19,125 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      1/19/24 4:21:50 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mcbrinn Sylvia bought $9,320 worth of shares (4,000 units at $2.33), increasing direct ownership by 36% to 15,125 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      12/26/23 7:43:02 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Short Jay M Phd bought $106,910 worth of shares (50,000 units at $2.14), increasing direct ownership by 4% to 1,439,283 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      12/20/23 6:27:44 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BCAB
    Financials

    Live finance-specific insights

    See more
    • BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

      CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark survival of 59% in mKRAS non-small cell lung cancer (NSCLC); Previous studies have reported 2-year landmark survival less than 20% among patients treated with standard of care agentsOzuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study continues to demonstrate compelling signals in HPV-positive squamous cell carcinoma of the head and neck (SCCHN) patients; Company utilizing Fas

      5/6/25 4:05:00 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla to Participate in the Citizens Life Sciences Conference

      SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will provide a corporate update and participate in one-on-one investor meetings at the Citizens Life Sciences Conference, to be held in New York, NY May 7-8, 2025. Format: Corporate update and one-on-one investor meetingsDate: Wednesday, May 7, 2025Time: 10:00 a.m. ETLocation: New York, NYWebcast Link: Click Here About BioAtla®, Inc.BioAtla is a global clinical-stage biotechnology company with operation

      4/30/25 8:00:00 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

      SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025 and provide business highlights. Conference Call and Webcast Information        Date: Tuesday, May 6, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla First Quarter 2025 Earnings Conference Call Dial-in Numbers: (800) 245-3047 (domestic), (203) 518-9765 (international)Con

      4/29/25 8:00:00 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

      CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark survival of 59% in mKRAS non-small cell lung cancer (NSCLC); Previous studies have reported 2-year landmark survival less than 20% among patients treated with standard of care agentsOzuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study continues to demonstrate compelling signals in HPV-positive squamous cell carcinoma of the head and neck (SCCHN) patients; Company utilizing Fas

      5/6/25 4:05:00 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

      SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025 and provide business highlights. Conference Call and Webcast Information        Date: Tuesday, May 6, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla First Quarter 2025 Earnings Conference Call Dial-in Numbers: (800) 245-3047 (domestic), (203) 518-9765 (international)Con

      4/29/25 8:00:00 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

      CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated with exceptional overall survival (OS) with 66% and 58% of patients with mKRAS NSCLC alive at a landmark one-year and two-years, respectively, which exceeds the reported standard of care Ozuriftamab vedotin (CAB-ROR2-ADC) demonstrated compelling anti-tumor activity in treatment-refractory, metastatic HPV-positive squamous cell carcinoma of the head and neck (SCCHN); a population which is poorly served by EGFR inhibitorsCash balance of $49mm at year-end 2024 with recent cost-redu

      3/27/25 4:05:00 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BioAtla Inc.

      SC 13G/A - BioAtla, Inc. (0001826892) (Subject)

      11/14/24 4:00:05 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BioAtla Inc.

      SC 13D/A - BioAtla, Inc. (0001826892) (Subject)

      10/2/24 4:30:04 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BioAtla Inc.

      SC 13D/A - BioAtla, Inc. (0001826892) (Subject)

      9/6/24 4:59:38 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BioAtla downgraded by H.C. Wainwright

      H.C. Wainwright downgraded BioAtla from Buy to Neutral

      11/13/24 7:31:56 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on BioAtla with a new price target

      JMP Securities initiated coverage of BioAtla with a rating of Mkt Outperform and set a new price target of $17.00

      9/15/22 7:31:28 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla downgraded by Credit Suisse with a new price target

      Credit Suisse downgraded BioAtla from Outperform to Neutral and set a new price target of $5.00 from $35.00 previously

      5/5/22 6:12:47 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care